{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:55:03Z","timestamp":1792652103031,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Tousled-like kinase 2 (TLK2) is a serine\/threonine kinase that plays a role in DNA replication, chromatin remodeling, and DNA damage response. TLK2 has been implicated in the pathogenesis of various types of cancer, including breast cancer, glioblastoma, and acute myeloid leukemia (AML). However, no potent and selective TLK2 inhibitors have been developed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated the efficacy of a human TLK2 antisense oligonucleotide (ASO) alone and in combination with gilteritinib in AML cell lines. To assess in vivo efficacy and toxicity, we administered a mouse TLK2 ASO alone or in combination with gilteritinib in a murine model of AML.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TLK2 ASO treatment resulted in a dose-dependent reduction of TLK2 mRNA levels and decreased cell viability in FLT3-mutant AML cell lines, with enhanced cytotoxicity observed when combined with gilteritinib. In a murine AML model, TLK2 ASO achieved approximately 50% knockdown efficiency. Both TLK2 ASO alone and in combination with gilteritinib significantly reduced spleen size, leukemia burden, and bone marrow progenitor cell populations. The treatment was generally well tolerated, with only minimal toxicity observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This study demonstrates that TLK2 ASO is a promising therapeutic strategy for AML, particularly in combination with FLT3 inhibition, and may apply to other TLK2-driven cancers. Future efforts should focus on improving ASO delivery and knockdown efficiency to maximize therapeutic benefit.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1659341","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:23:00Z","timestamp":1773033780000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting TLK2 with antisense oligonucleotides as a new strategy in acute myeloid leukemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Hsin-Yun","family":"Lin","sequence":"first","affiliation":[{"name":"Division of Oncological Sciences, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Department of Molecular and Medical Genetics, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Knight Cancer Institute, Oregon Health & Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sokchea","family":"Khou","sequence":"additional","affiliation":[{"name":"Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Knight Cancer Institute, Oregon Health & Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Lind","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Department of Molecular Microbiology and Immunology, Oregon Health & Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katia G.","family":"de Oliveira Rebola","sequence":"additional","affiliation":[{"name":"Division of Oncological Sciences, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Department of Molecular and Medical Genetics, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Knight Cancer Institute, Oregon Health & Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Dean","sequence":"additional","affiliation":[{"name":"Division of Oncological Sciences, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Department of Molecular and Medical Genetics, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Knight Cancer Institute, Oregon Health & Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haijiao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Division of Oncological Sciences, Oregon Health & Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Tolentino","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc.","place":["Carlsbad, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Maazi","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc.","place":["Carlsbad, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Revenko","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc.","place":["Carlsbad, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupriya","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Oncological Sciences, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Department of Molecular and Medical Genetics, Oregon Health & Science University","place":["Portland, OR, United States"]},{"name":"Knight Cancer Institute, Oregon Health & Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28129","article-title":"Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades","volume":"119","author":"Thein","year":"2013","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.28098","article-title":"Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity","volume":"119","author":"Patel","year":"2013","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1177\/1947601911408076","article-title":"Genetic abnormalities and challenges in the treatment of acute myeloid leukemia","volume":"2","author":"Kumar","year":"2011","journal-title":"Genes Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022079","article-title":"The TLK-ASF1 histone chaperone pathway plays a critical role in IL-1beta-mediated AML progression","volume":"143","author":"Lin","year":"2024","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.108","article-title":"Differential requirements for Tousled-like kinases 1 and 2 in mammalian development","volume":"24","author":"Segura-Bayona","year":"2017","journal-title":"Cell Death Differ"},{"key":"B7","doi-asserted-by":"publisher","first-page":"eaat4985","DOI":"10.1126\/sciadv.aat4985","article-title":"Tousled-like kinases stabilize replication forks and show synthetic lethality with checkpoint and PARP inhibitors","volume":"4","author":"Lee","year":"2018","journal-title":"Sci Adv"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-04941-y","article-title":"Molecular basis of Tousled-Like Kinase 2 activation","volume":"9","author":"Mortuza","year":"2018","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2018.1507257","article-title":"TLK2 enhances aggressive phenotypes of glioblastoma cells through the activation of SRC signaling pathway","volume":"20","author":"Lin","year":"2019","journal-title":"Cancer Biol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12991","article-title":"Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers","volume":"7","author":"Kim","year":"2016","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03208-z","article-title":"The Tousled-like kinases regulate genome and epigenome stability: implications in development and disease","volume":"76","author":"Segura-Bayona","year":"2019","journal-title":"Cell Mol Life Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113904","article-title":"Design, synthesis and biological evaluation of bisindole derivatives as anticancer agents against Tousled-like kinases","volume":"227","author":"Lee","year":"2022","journal-title":"Eur J Med Chem"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2014.00087","article-title":"Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic","volume":"2","author":"Moreno","year":"2014","journal-title":"Front Chem"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.12.1344","article-title":"Antisense molecules: A new class of drugs","volume":"137","author":"Potaczek","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.03.023","article-title":"FDA-approved oligonucleotide therapies in 2017","volume":"25","author":"Stein","year":"2017","journal-title":"Mol Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1021\/jm801294h","article-title":"Short antisense oligonucleotides with novel 2\u2019-4\u2019 conformationaly restricted nucleoside analogues show improved potency without increased toxicity in animals","volume":"52","author":"Seth","year":"2009","journal-title":"J Med Chem"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"Finkel","year":"2017","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010097","article-title":"Making sense of antisense oligonucleotide therapeutics targeting bcl-2","volume":"14","author":"Gagliardi","year":"2022","journal-title":"Pharmaceutics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI120156","article-title":"Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells","volume":"128","author":"Shastri","year":"2018","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e13255","DOI":"10.1111\/cpr.13255","article-title":"CD33-targeting extracellular vesicles deliver antisense oligonucleotides against FLT3-ITD and miR-125b for specific treatment of acute myeloid leukaemia","volume":"55","author":"Chen","year":"2022","journal-title":"Cell Prolif"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30021-8","article-title":"Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological Malignancies: a single-centre, open-label, dose-escalation, phase 1\/1b trial","volume":"5","author":"Ohanian","year":"2018","journal-title":"Lancet Haematol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003892","article-title":"Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer","volume":"10","author":"Revenko","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btw230","article-title":"Combenefit: an interactive platform for the analysis and visualization of drug combinations","volume":"32","author":"Di Veroli","year":"2016","journal-title":"Bioinformatics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkac382","article-title":"SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples","volume":"50","author":"Ianevski","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-2654","article-title":"Targeting CCL2\/CCR2 signaling overcomes MEK inhibitor resistance in acute myeloid leukemia","volume":"30","author":"Modak","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1045","article-title":"The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3","volume":"101","author":"Spiekermann","year":"2003","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e70055","DOI":"10.1002\/cncr.70055","article-title":"Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experience","volume":"131","author":"Cairoli","year":"2025","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"9288","DOI":"10.1038\/s41467-025-64066-x","article-title":"Chromatin looping-based CRISPR screen identifies TLK2 as chromatin loop formation regulator in cancer stemness plasticity","volume":"16","author":"Wang","year":"2025","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101474","article-title":"Generation of phenothiazine with potent anti-TLK1 activity for prostate cancer therapy","volume":"23","author":"Singh","year":"2020","journal-title":"iScience"},{"key":"B30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1177\/1947601913479020","article-title":"Phenothiazine inhibitors of TLKs affect double-strand break repair and DNA damage response recovery and potentiate tumor killing with radiomimetic therapy","volume":"4","author":"Ronald","year":"2013","journal-title":"Genes Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2019.03.041","article-title":"The TLK1-Nek1 axis promotes prostate cancer progression","volume":"453","author":"Singh","year":"2019","journal-title":"Cancer Lett"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1169","article-title":"The role of FLT3 in haematopoietic Malignancies","volume":"3","author":"Stirewalt","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S507402","article-title":"Lipid nanovesicles in cancer treatment: improving targeting and stability of antisense oligonucleotides","volume":"19","author":"Ding","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1659341\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T05:23:01Z","timestamp":1773033781000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1659341\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,9]]},"references-count":36,"alternative-id":["10.3389\/fonc.2026.1659341"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1659341","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,9]]},"article-number":"1659341"}}